Forendo Pharma Ltd. received a €4 million funding from private equity firm Vesalius Biocapital III.
Vesalius Biocapital III Partners is a fund managed by Vesalius Biocapital Partners S.à r.l. and invests in later stage European life science companies in drug development, medtech, diagnostics and eHealth.
As part of the investment, Vesalius' Managing Partner Stéphane Verdood will join the Forendo Pharma board.
The funding enables Forendo, a portfolio company of Karolinska Development AB, to accelerate development of its women's health product candidates.
The company's lead program, known as FOR 6219, is being developed to treat endometriosis — a gynecological disorder that affects up to 10% of women in reproductive age.